Novo Nordisk slides on patent cliff worries after cautious growth targets
TL;DR Summary
Novo Nordisk shares fell more than 7% after its Capital Markets Day failed to reassure investors about weight‑loss drug competition and looming semaglutide patent expiry, as the company projects five multi‑blockbuster drugs by 2030 and over 150 billion Danish kroner in risk‑adjusted pipeline sales by 2035, while acknowledging a CagriSema Phase 3 miss and tight competition in the obesity drug market (Lilly leads ~61% vs Novo's ~39%).
- Novo Nordisk shares plunge over 7% as new targets fail to reassure investors Yahoo Finance
- Wegovy Maker Novo Promises New Drugs to Boost Sales, but Investors Are Wary WSJ
- Novo Nordisk stock gets drilled on pipeline concerns— its CEO sees this as the main problem Yahoo Finance
- Novo shares slide as drugmaker lays out post-Wegovy growth strategy CNBC
- Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting BioSpace
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
20 min
vs 21 min read
Condensed
98%
4,148 → 67 words
Want the full story? Read the original article
Read on Yahoo Finance